title: [Prolongation of survival and antitumor activity of antitumor drugs in murine cancer cachexia model].
abstract: We examined the activity of UFT, ADM and MMC, which are used for colon tumors, in terms of their prolongation of the survival period, growth inhibition of the primary tumor and improvement of cachexia in murine cancer cachexia model. The mean survival period of Colon 26, mouse adenocarcinoma bearing mice was 25.0 +/- 4.9 days. The maximal ILS value of the UFT administered group was 103.2%, against 7.2 and 26.0%, respectively, ADM and MMC maximal ILS value. For therapeutic activity of hypercalcemia, UFT was superior to other drugs, although all drugs showed equivalent tumor growth inhibitory activity. These findings indicate that UFT can prolong the survival period due to improvement of cancer cachexia. Therefore, we measured plasma interleukin-6 (IL-6) and found that UFT-administration lowered the plasma IL-6 level more than other drugs. Moreover, the prostaglandin E2 (PGE2) level in the tumor was significantly decreased only by UFT-administration. Since PGE2 has been shown to enhance IL-6 production from Colon 26 in vitro, it was speculated that UFT improve cachexia and prolongs life by decreased IL-6 resulting from decreased PGE2.
authors.affiliation: Anticancer and Antimicrobial Research Lab, Taiho Pharmaceutical Co., Ltd., Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nukatsuka
authors.forename: A
authors.initials: A
authors.lastname: Fujioka
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: J
authors.initials: J
authors.lastname: Uchida
authors.forename: S
authors.initials: S
authors.lastname: Takeda
authors.forename: N
authors.initials: N
authors.lastname: Unemi
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002100:Cachexia / Q000188:drug therapy* / Q000276:immunology; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D015232:Dinoprostone / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage; D004338:Drug Combinations; D015850:Interleukin-6 / Q000096:biosynthesis; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016685:Mitomycin / Q000008:administration & dosage; D016019:Survival Analysis; D005641:Tegafur / Q000008:administration & dosage; D014407:Tumor Cells, Cultured; D014498:Uracil / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D015850:Interleukin-6; C096910:UFT(R) drug; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil; D004317:Doxorubicin; D015232:Dinoprostone